🇺🇸 American Board of Internal Medicine Certification (ABIM Board Certification) · subject

American Board of Internal Medicine Certification (ABIM Board Certification) Pulmonary & Critical Care Medicine Syllabus

The Pulmonary & Critical Care Medicine syllabus for American Board of Internal Medicine Certification (ABIM Board Certification) in full: 5 chapters, 19 topics and 7 sub-topics, every one listed below, plus 60 Pulmonary & Critical Care Medicine flashcards with answers.

5Chapters
19Topics
7Sub-topics
60Flashcards

Pulmonary & Critical Care Medicine syllabus: all 5 chapters

Expand any chapter to see its topics and sub-topics.

  1. Obstructive & Airway Diseases

    3 topics
    • COPD diagnosis, GOLD staging, and management
      • Inhaler therapy escalation
      • Acute exacerbation treatment
    • Asthma classification and stepwise therapy
    • Bronchiectasis and cystic fibrosis
  2. Interstitial & Diffuse Parenchymal Lung Disease

    4 topics
    • Idiopathic pulmonary fibrosis
    • Hypersensitivity pneumonitis
    • Sarcoidosis
      • Pulmonary and extrapulmonary manifestations
    • Connective tissue disease-associated ILD
  3. Pulmonary Vascular & Pleural Disease

    4 topics
    • Pulmonary embolism diagnosis and risk stratification
      • Wells/PERC criteria and D-dimer use
      • Thrombolysis and anticoagulation
    • Pulmonary hypertension classification
    • Pleural effusion: Light's criteria and workup
    • Pneumothorax management
  4. Respiratory Failure & Mechanical Ventilation

    4 topics
    • ARDS recognition and lung-protective ventilation
    • Hypoxemic vs hypercapnic respiratory failure
    • Noninvasive ventilation indications
    • Ventilator settings and weaning
  5. Shock & Critical Illness

    4 topics
    • Sepsis and septic shock management
      • Early resuscitation and source control
      • Vasopressor selection
    • Shock classification and hemodynamic assessment
    • Sleep-disordered breathing and OSA
    • Acid-base interpretation in critical illness

American Board of Internal Medicine Certification (ABIM Board Certification) Pulmonary & Critical Care Medicine flashcards — 60 questions with answers

  1. What spirometry finding is required to diagnose COPD?

    A post-bronchodilator FEV1/FVC ratio < 0.70, confirming persistent, non-fully-reversible airflow obstruction.

  2. Describe the GOLD spirometric grades (1-4) of airflow limitation based on post-bronchodilator FEV1 % predicted (in patients with FEV1/FVC < 0.70).

    GOLD 1 (mild): FEV1 >=80%; GOLD 2 (moderate): 50-79%; GOLD 3 (severe): 30-49%; GOLD 4 (very severe): <30% predicted.

  3. How does the GOLD ABE assessment tool classify COPD patients?

    By symptoms (mMRC/CAT) and exacerbation history: Group A = low symptoms, 0-1 non-hospitalized exacerbations; Group B = high symptoms, 0-1 exacerbations; Group E = >=2 moderate exacerbations or >=1 leading to hospitalization (regardless of symptoms).

  4. Which two interventions have been proven to reduce mortality in COPD?

    Smoking cessation and long-term supplemental oxygen therapy in patients with chronic resting hypoxemia (lung volume reduction surgery also benefits selected upper-lobe predominant patients).

  5. What are the criteria for prescribing long-term oxygen therapy in COPD?

    Resting PaO2 <=55 mmHg or SaO2 <=88%; or PaO2 56-59 mmHg (SaO2 89%) with evidence of cor pulmonale, right heart failure, or erythrocytosis (Hct >55%).

  6. When should inhaled corticosteroids be added to therapy in COPD?

    Favored when blood eosinophils are elevated (>=300 cells/uL, consider at >=100) and/or frequent exacerbations despite LABA/LAMA; ICS are avoided in patients with low eosinophils due to increased pneumonia risk.

  7. What is the role of roflumilast in COPD?

    A PDE-4 inhibitor used to reduce exacerbations in patients with severe COPD, chronic bronchitis phenotype, and frequent exacerbations despite inhaled triple therapy.

  8. What young patient or basilar-emphysema presentation should prompt testing for alpha-1 antitrypsin deficiency?

    COPD/emphysema in a patient <45 years, a nonsmoker or minimal smoking history, basilar-predominant emphysema, or associated unexplained liver disease.

  9. In asthma, what spirometric change defines significant bronchodilator reversibility?

    An increase in FEV1 (or FVC) of >=12% AND >=200 mL after a bronchodilator.

  10. How is asthma severity classified by symptom frequency (intermittent vs persistent)?

    Intermittent: symptoms <=2 days/week, nighttime <=2x/month, FEV1 normal. Mild persistent: >2 days/week but not daily. Moderate persistent: daily symptoms, nighttime >1x/week. Severe persistent: throughout the day, frequent nighttime, FEV1 <60%.

  11. What is the preferred reliever therapy in current (GINA) stepwise asthma management for adults?

    As-needed low-dose ICS-formoterol (anti-inflammatory reliever), rather than SABA alone, across steps 1-2; SABA-only treatment is no longer recommended.

  12. What is the SMART/MART strategy in asthma?

    Single Maintenance And Reliever Therapy: using a single ICS-formoterol inhaler for both daily maintenance and as-needed relief, which reduces exacerbations.

  13. Which biologics target which pathways in severe eosinophilic/allergic asthma?

    Omalizumab (anti-IgE) for allergic asthma; mepolizumab/reslizumab (anti-IL-5) and benralizumab (anti-IL-5R) for eosinophilic asthma; dupilumab (anti-IL-4Ra) for type 2/eosinophilic asthma.

  14. What is the classic radiographic and clinical hallmark of bronchiectasis?

    Permanent, abnormal bronchial dilation with chronic productive cough; high-resolution CT shows airways larger than the accompanying artery ('signet ring' sign), lack of tapering, and bronchial wall thickening.

  15. What is the most common genetic defect causing cystic fibrosis, and how is it diagnosed?

    The Phe508del (F508del) mutation in the CFTR gene; diagnosed by an elevated sweat chloride >=60 mmol/L and/or two disease-causing CFTR mutations with clinical features.

  16. Which organisms most commonly colonize/infect the airways in cystic fibrosis over time?

    Staphylococcus aureus in childhood, then chronic Pseudomonas aeruginosa (associated with worse prognosis); also Burkholderia cepacia complex, which carries a poor prognosis.

  17. What class of drugs has transformed cystic fibrosis treatment?

    CFTR modulators (e.g., elexacaftor/tezacaftor/ivacaftor, 'Trikafta') that correct/potentiate the defective CFTR protein, improving lung function and reducing exacerbations.

  18. What is the characteristic HRCT pattern of idiopathic pulmonary fibrosis (IPF)?

    Usual interstitial pneumonia (UIP): subpleural and basal-predominant reticulation with honeycombing, with or without traction bronchiectasis, and minimal ground-glass.

  19. Which two antifibrotic drugs slow disease progression in IPF?

    Pirfenidone and nintedanib; both slow the decline in FVC. Corticosteroids/immunosuppression are NOT beneficial and may be harmful in IPF.

  20. What exposure history and CT features suggest chronic hypersensitivity pneumonitis?

    Exposure to organic antigens (birds, molds, hot tubs, farming); CT shows centrilobular ground-glass nodules, mosaic attenuation/air trapping (three-density 'headcheese' sign), and upper/mid-lung fibrosis. BAL typically shows lymphocytosis.

Show the other 40 Pulmonary & Critical Care Medicine flashcards
  1. What are the classic chest imaging and biopsy findings of pulmonary sarcoidosis?

    Bilateral hilar lymphadenopathy with reticulonodular opacities (often upper-lobe); biopsy shows non-caseating granulomas. Stage I = hilar adenopathy alone; Stage IV = fibrosis.

  2. Name two acute sarcoidosis syndromes and the first-line systemic therapy for symptomatic disease.

    Lofgren syndrome (erythema nodosum, hilar adenopathy, arthralgia/fever - good prognosis) and Heerfordt syndrome (uveoparotid fever, facial palsy). First-line systemic therapy is corticosteroids.

  3. Why must hypercalcemia be monitored in sarcoidosis?

    Granulomas express 1-alpha-hydroxylase, increasing conversion of 25-OH vitamin D to active 1,25-(OH)2 vitamin D, causing hypercalcemia, hypercalciuria, and nephrolithiasis.

  4. Which connective tissue diseases are most commonly associated with ILD, and which serologies suggest it?

    Systemic sclerosis (most common, often NSIP pattern), rheumatoid arthritis (often UIP), polymyositis/dermatomyositis, Sjogren, and MCTD. Antibodies: anti-Scl-70, anti-Jo-1 (antisynthetase), anti-MDA5, anti-CCP.

  5. What is the most common histologic ILD pattern in connective tissue disease (vs IPF)?

    Nonspecific interstitial pneumonia (NSIP), which is more steroid/immunosuppressant-responsive and has a better prognosis than the UIP pattern seen in IPF.

  6. What is the Wells score used for, and what does a low pretest probability with a negative D-dimer indicate?

    Wells score estimates pretest probability of pulmonary embolism; a low/unlikely probability plus a negative high-sensitivity D-dimer reliably excludes PE without imaging.

  7. What is the PERC rule for pulmonary embolism?

    In patients with low clinical suspicion, if all 8 PERC criteria are negative (age <50, HR <100, SaO2 >=95%, no hemoptysis, no estrogen use, no prior DVT/PE, no unilateral leg swelling, no recent surgery/trauma), PE can be excluded without D-dimer testing.

  8. How are pulmonary emboli risk-stratified into massive, submassive, and low-risk categories?

    Massive (high-risk): hypotension/shock (SBP <90). Submassive (intermediate): normotensive but with RV dysfunction (echo/CT) and/or elevated troponin/BNP. Low-risk: normotensive, no RV strain, normal biomarkers.

  9. When is systemic thrombolysis indicated in acute PE?

    In massive (high-risk) PE with hemodynamic instability/hypotension, provided no contraindication to bleeding; selected deteriorating submassive PE may be considered (catheter-directed therapy is an alternative).

  10. List the 5 WHO groups of pulmonary hypertension.

    Group 1: pulmonary arterial hypertension (PAH). Group 2: due to left heart disease. Group 3: due to lung disease/hypoxia. Group 4: chronic thromboembolic (CTEPH). Group 5: multifactorial/unclear mechanisms.

  11. What is the hemodynamic definition of pulmonary hypertension (current criteria)?

    Mean pulmonary artery pressure >20 mmHg at rest by right heart catheterization. Pre-capillary PH adds PVR >2 Wood units and PAWP <=15 mmHg.

  12. How do you distinguish pre-capillary from post-capillary pulmonary hypertension?

    Pre-capillary (Groups 1,3,4): PAWP <=15 mmHg with elevated PVR. Post-capillary (Group 2): PAWP >15 mmHg (elevated left-sided filling pressures).

  13. State Light's criteria for an exudative pleural effusion.

    Exudate if ANY one is met: pleural/serum protein ratio >0.5; pleural/serum LDH ratio >0.6; or pleural fluid LDH >2/3 the upper limit of normal serum LDH.

  14. What pleural fluid findings suggest the need for chest tube drainage in a parapneumonic effusion (complicated effusion/empyema)?

    Pleural fluid pH <7.2, glucose <60 mg/dL, positive Gram stain/culture, or frank pus (empyema) indicate a complicated effusion requiring drainage.

  15. What pleural fluid characteristics suggest a transudate, and name two common causes.

    Fails all Light's criteria (low protein/LDH), typically clear; common causes are heart failure and cirrhosis (hepatic hydrothorax); also nephrotic syndrome.

  16. What does a markedly elevated pleural fluid lymphocyte count plus high adenosine deaminase suggest?

    Tuberculous pleuritis (lymphocyte-predominant exudate with ADA >40 U/L); malignancy and lymphoma can also cause lymphocytic effusions.

  17. What is the initial management of a primary spontaneous pneumothorax that is small and the patient stable?

    Observation with supplemental oxygen (oxygen speeds pleural air resorption); needle aspiration or small-bore catheter is an option. Large/symptomatic pneumothorax requires aspiration or chest tube.

  18. How is a tension pneumothorax recognized and immediately treated?

    Hypotension, distended neck veins, tracheal deviation away, absent breath sounds, hyperresonance; treat immediately with needle decompression (2nd intercostal space midclavicular line or 4th/5th anterior axillary) followed by chest tube - do NOT wait for imaging.

  19. State the Berlin definition diagnostic criteria for ARDS.

    Acute onset within 1 week; bilateral opacities on imaging not fully explained by effusions/collapse; respiratory failure not fully explained by cardiac failure/fluid overload; and hypoxemia by PaO2/FiO2 ratio with PEEP/CPAP >=5.

  20. How is ARDS severity graded by PaO2/FiO2 ratio (with PEEP >=5)?

    Mild: 200-300 mmHg; Moderate: 100-200 mmHg; Severe: <=100 mmHg.

  21. What are the core lung-protective ventilation targets in ARDS?

    Low tidal volume 6 mL/kg predicted body weight, plateau pressure <=30 cmH2O, driving pressure <15, permissive hypercapnia, and adequate PEEP; this strategy reduces mortality (ARDSNet).

  22. Which adjunct therapy reduces mortality in severe ARDS (P/F <150)?

    Early prone positioning (e.g., 16 hours/day) improves oxygenation and reduces mortality; neuromuscular blockade may be used in selected severe cases.

  23. Differentiate hypoxemic (type 1) from hypercapnic (type 2) respiratory failure.

    Type 1 (hypoxemic): low PaO2 with normal/low PaCO2, due to V/Q mismatch or shunt (e.g., pneumonia, ARDS, edema). Type 2 (hypercapnic): elevated PaCO2 with hypoxemia, due to alveolar hypoventilation (e.g., COPD, neuromuscular disease, drug overdose).

  24. What is the alveolar gas equation and the normal A-a gradient?

    PAO2 = (FiO2 x [Patm - PH2O]) - (PaCO2/R); at sea level on room air ~150 - (PaCO2/0.8). Normal A-a gradient is ~5-15 mmHg, increasing with age (estimate = age/4 + 4).

  25. A patient has hypoxemia with a NORMAL A-a gradient. What are the two causes?

    Hypoventilation and low inspired oxygen (high altitude). A widened A-a gradient instead indicates V/Q mismatch, shunt, or diffusion limitation.

  26. What are the two best-established indications for noninvasive positive pressure ventilation (NIPPV)?

    Acute hypercapnic respiratory failure from COPD exacerbation (respiratory acidosis pH <7.35) and cardiogenic pulmonary edema; both reduce intubation rates and mortality.

  27. List contraindications to noninvasive ventilation.

    Cardiac/respiratory arrest, inability to protect airway/impaired consciousness, excessive secretions, facial trauma/surgery, hemodynamic instability/shock, and high aspiration risk or uncooperative patient.

  28. On a mechanical ventilator, which settings primarily control oxygenation vs ventilation (CO2 removal)?

    Oxygenation is controlled by FiO2 and PEEP; ventilation (CO2 clearance) is controlled by respiratory rate and tidal volume (minute ventilation).

  29. What criteria suggest a patient is ready for a spontaneous breathing trial (SBT) and likely successful extubation?

    Resolution/improvement of underlying cause, adequate oxygenation (P/F >150, PEEP <=5-8, FiO2 <=0.4-0.5), hemodynamic stability off/minimal pressors, and a rapid shallow breathing index (RR/Vt) <105.

  30. Define sepsis and septic shock per Sepsis-3.

    Sepsis = life-threatening organ dysfunction (acute SOFA increase >=2) due to a dysregulated host response to infection. Septic shock = sepsis requiring vasopressors to maintain MAP >=65 mmHg AND lactate >2 mmol/L despite adequate fluid resuscitation.

  31. What are the key components of the initial 'hour-1' sepsis bundle?

    Measure lactate (remeasure if >2), obtain blood cultures before antibiotics, give broad-spectrum antibiotics, begin 30 mL/kg crystalloid for hypotension or lactate >=4, and add vasopressors to keep MAP >=65 if hypotensive during/after fluids.

  32. What is the first-line vasopressor in septic shock, and what is added if MAP remains low?

    Norepinephrine is first-line; vasopressin (and/or epinephrine) is added next, and consider stress-dose hydrocortisone in refractory shock requiring escalating vasopressors.

  33. Compare the hemodynamic profiles (CO, SVR, PCWP/preload) of the four shock types.

    Hypovolemic: low CO, high SVR, low preload. Cardiogenic: low CO, high SVR, high PCWP. Obstructive: low CO, high SVR, variable filling (high CVP). Distributive (septic): high/normal CO, low SVR, low/normal preload.

  34. Interpret a single arterial blood gas: pH 7.20, PaCO2 60, HCO3 24. What is the disorder?

    Acute respiratory acidosis (low pH, high PaCO2 with minimal HCO3 compensation). Acutely, HCO3 rises ~1 mEq/L per 10 mmHg rise in PaCO2.

  35. How do you calculate the anion gap and what does an elevated anion gap metabolic acidosis suggest (mnemonic)?

    Anion gap = Na - (Cl + HCO3), normal ~8-12. Elevated gap causes (GOLD MARK or MUDPILES): glycols, oxoproline, L-lactate, D-lactate, methanol, aspirin, renal failure, ketoacidosis (and uremia, DKA, propylene glycol, iron/INH, lactate, ethylene glycol, salicylates).

  36. What is Winter's formula and what does it assess?

    Expected PaCO2 = 1.5 x HCO3 + 8 (+/- 2). It checks for appropriate respiratory compensation in metabolic acidosis; a higher PaCO2 indicates a concurrent respiratory acidosis, a lower one a respiratory alkalosis.

  37. How is obstructive sleep apnea diagnosed and graded by the apnea-hypopnea index (AHI)?

    Diagnosed by polysomnography (or home sleep apnea test). AHI 5-14 = mild, 15-29 = moderate, >=30 = severe (AHI = number of apneas + hypopneas per hour of sleep).

  38. What is the first-line treatment for moderate-to-severe obstructive sleep apnea, and what cardiovascular conditions is OSA associated with?

    Continuous positive airway pressure (CPAP) is first-line; OSA is associated with hypertension (especially resistant), atrial fibrillation, heart failure, pulmonary hypertension, stroke, and increased perioperative risk.

  39. How does obesity hypoventilation syndrome differ from obstructive sleep apnea?

    OHS is defined by obesity (BMI >=30) with awake daytime hypercapnia (PaCO2 >45 mmHg) not explained by other causes; it is chronic hypercapnic respiratory failure, whereas OSA is primarily upper-airway obstruction without mandatory daytime hypercapnia.

  40. What is central sleep apnea and a classic pattern seen in heart failure?

    Cessation of airflow due to loss of ventilatory drive (no respiratory effort), unlike obstructive apnea. Cheyne-Stokes respiration (crescendo-decrescendo breathing with central apneas) is classically seen in heart failure and after stroke.

American Board of Internal Medicine Certification (ABIM Board Certification) Pulmonary & Critical Care Medicine FAQ

What is in the American Board of Internal Medicine Certification (ABIM Board Certification) Pulmonary & Critical Care Medicine syllabus?

American Board of Internal Medicine Certification (ABIM Board Certification) Pulmonary & Critical Care Medicine is split into 5 chapters: Obstructive & Airway Diseases, Interstitial & Diffuse Parenchymal Lung Disease, Pulmonary Vascular & Pleural Disease, Respiratory Failure & Mechanical Ventilation and Shock & Critical Illness. Together they contain 19 topics and 7 sub-topics.

How many chapters are in American Board of Internal Medicine Certification (ABIM Board Certification) Pulmonary & Critical Care Medicine?

5 chapters, containing 19 topics and 7 sub-topics. The largest chapter is Interstitial & Diffuse Parenchymal Lung Disease, with 4 topics.

Are there flashcards for American Board of Internal Medicine Certification (ABIM Board Certification) Pulmonary & Critical Care Medicine?

Yes — a 60-card Pulmonary & Critical Care Medicine deck, printed in full in the flashcards section of this page and available in the Examius app with spaced repetition. The free plan covers one exam of your choice, including its flashcards; Examius Pro, a one-time purchase, unlocks every other exam and deck.